Project Details
Description
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/16 → 11/30/18 |
Funding
- DYNAVAX TECHNOLOGIES CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.